Preterm Birth Prevention and Management Market to Surpass US$ 2 Bn in 2026
Preterm birth is among the prevalent public health concerns all over the world and has become the primary cause of mortality in children aging below 5 years. To curb the alarming situation, governments including, the Food and Drug Administration (FDA), are showing immediacy in approving drugs for preterm birth prevention and management. In addition, they are increasing their healthcare spending in order to encourage novel generic drug development and establish advanced healthcare infrastructure. In line with these trends, the global preterm birth prevention and management market will cross the US$ 2 Bn mark towards the end of forecast period, 2019-2029.
Frequently Asked Questions about Preterm Birth Prevention and Management Market
What are the factors contributing to growth of the preterm birth prevention and management market?
Growing focus on targeted therapies and standard of care, particularly in the area of preterm birth, is increasing the need for preterm birth prevention and management drugs. Progesterone therapy hold a notable share of the preterm birth prevention and management market. Adoption of preterm birth prevention and management drug in developing economies is anticipated to gain significant traction.
What are the promising strategies for large manufacturers and small local players contributing to growth of the preterm birth prevention and management market?
The higher fragmented nature of the market particularly with progesterone therapy and the availability of optional intervention hampers the profitability of the business. However, increasing awareness about preterm birth prevention and management and growing demand for cost-effective treatment options for preterm birth prevention have increased the revenue opportunities for global manufacturers.
Which country is growing at highest pace in preterm birth prevention and management market during the forecast period?
The Preterm Birth Prevention and Management market in India is expected to witness significant growth due to highest number of preterm births coupled with affordability of preterm birth prevention and management therapies in country.
What are the initiatives taken up by organization that can aid growth of the preterm birth prevention and management hampering market?
Initiatives take up by various regional and international organizations in order to address on-going preterm birth scenario, and health inequities, help various healthcare facilities in research, advocacy, education, and healthcare innovation and community engagement for preterm birth. Pointedly offering growth opportunities for preterm birth prevention and management market.
Which region is expected to offer lucrative growth opportunities for the preterm birth prevention and management market?
North America and South Asia, being highly mature markets with higher concentration of manufacturers and healthcare resources, are estimated to drive growth of the global preterm birth prevention and management market. Furthermore, East Asia and South Asia are expected to be lucrative regions, as majority of manufacturers of low cost preterm birth prevention and management are focusing to establish facilities in these regions.
How is the competition scenario in the preterm birth prevention and management market?
Manufacturers in the preterm birth prevention and management market such as Teva Pharmaceutical Industries Ltd., Pfizer Inc., Novartis AG, Sanofi S.A. are aiming on organic and inorganic business expansions strategies by entering into sales agreement, mergers, partnership, and production partnership with local contract manufactures from developing economies. While key players like AMAG Pharmaceuticals, Ferring Pharmaceuticals, are opting for development of product associated USPs to leverage brand identity.
Progesterone Therapy Remains the Preferable Medication
Healthcare providers usually prefer progesterone therapy owing to its fast action, and better efficacy. Recommended for patients with a history of preterm birth, the medication does not require surgery or anesthesia. FMI underlines that the adoption of progesterone therapy would accent over US$ 1 Bn in 2025. However, this preventative medication is expected to falter in the near term due to its side effects - mood swings, headaches, and bloating. Healthcare providers are thus turning to other therapies such as corticosteroid therapy, and tocolytics therapy.
North America’s Market Continues to Lead the Pack
Capturing about half total market value, North America continues to engage stakeholders over the due course of time. Conducive regulatory environment and reimbursement policies are the major forces driving the preterm birth prevention and management market in the developed region. Several organizations in the US are introducing initiatives to address the existing preterm birth scenario, and health inequities. Market players are also eyeing Asia for relevant value creation owing to increasing caseloads of preterm births coupled with cost-effective preterm birth prevention and management therapies.
* This data is only a representation. Actual data may vary and will be available in report.
Strategic Convening for Stronger Foothold
Market players are entering into strategic collaboration with various healthcare systems in order to create awareness regarding preterm births. For instance, Sera Prognostics, has collaborated with Christina Care Health System to launch a new preterm birth study with their preterm diagnostic test kit, PreTRM® that tests for IGFBP-1. Intermountain Health has collaborated with Christina Care Health System for two breakthrough preterm birth studies. As these partnerships gain momentum, incumbents are well placed to considerably enhance their business footprint.
Progesterone therapy remains highly preferred
Tocolytics therapy to pick pace
Preeclampsia patients remain primary target
Cases of prior spontaneous PTB to dip
Hospital pharmacies hold leading revenue share
Retail pharmacies to show higher CAGR
How Growth will Unfold
Shareholders continue to allocate their capitals to hospital pharmacies for distribution of preterm birth prevention and management drugs. Revenues generated through hospital pharmacies will boost over 2x during the foreseeable timeframe. Market players are also uncovering new revenue lines via retail and mail-order pharmacies, which collectively capture around a third of overall market stack. Despite this shift, the margin growth of hospital pharmacies would remain atop in the preterm birth prevention and management market.
* This data is only a representation. Actual data may vary and will be available in report.Click Here To Know How The Growth Will Unfold
Custom Market Research Services
FMI offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.
A recent market study published by Future Market Insights (FMI) offers global industry analysis for 2014-2018 and forecast for 2019-2029. The study also offers a comprehensive assessment of the most important market dynamics. After conducting thorough research on the historical as well as current growth parameters of the preterm birth prevention and management market, the growth prospects of the market are obtained with maximum precision.
Preterm Birth Prevention and Management Market Taxonomy
The market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.
- Progesterone Therapy
- Corticosteroid Therapy
- Tocolytics Therapy
- Antihypertensive Therapy
- Magnesium Sulfate Therapy
- Heparin Prophylaxis Therapy
- Low-Dose Aspirin Therapy
- Antibiotics Therapy
Route of Administration
- Prior Spontaneous PTB
- Short Cervix
- Chronic Hypertension
- Antiphospholipid Antibody Syndrome
- Hospital Pharmacies
- Retail Pharmacies
- Drug Stores
- Mail Order Pharmacies
- North America
- Latin America
- South Asia
- East Asia
- Middle East And Africa
The report commences with the executive summary of the preterm birth prevention and management market, which includes a summary of the key findings and key statistics of the market. It also includes the market value (US$ million) estimates of the leading segments of the market.
Readers can find the detailed segmentation and the definition of the market in this chapter, which will help them understand the basic information about the market. This section also highlights the inclusions and exclusions, which helps the reader understand the scope of the preterm birth prevention and management market report.
The report provides the key market trends that are expected to significantly impact the market growth during the forecast period. Detailed industry trends are provided in this section.
This chapter explains the key macroeconomic factors that are expected to influence the growth of the market during the forecast period. Along with the macroeconomic factors, this section also highlights the impact factors, supply chain, forecast factors, Porter’s five forces analysis, and value chain analysis for the market. Moreover, in-depth information about the market dynamics and their impact analysis on the market have been provided in the successive section. Moreover, readers will understand the key trends followed by the leading manufacturers in the market.
This section includes the factors that have emerged as key successful factors and the strategies adopted by key market participants. Additional viewpoint on global average pricing analysis benchmark, consumer sentiment analysis, and value chain analysis, which are likely to contribute to market growth.
This section includes the viewpoint on global average pricing analysis benchmark, based on therapy type.
This section explains the global market value analysis and forecast for the market between the forecast periods of 2019-2029. This chapter includes a detailed analysis of the historical market, along with an opportunity analysis of the future. Readers can also find the absolute $ opportunity for the current year (2019), and an incremental $ opportunity for the forecast period (2019-2029). Along with this, pricing analysis of the preterm birth prevention and management market at the regional level has been provided in this section. This section also explains the global market volume analysis and forecast for the market during the forecast period.
Based on therapy type, the market is segmented into progesterone therapy, corticosteroid therapy, tocolytics therapy, antihypertensive therapy, magnesium sulfate therapy, heparin prophylaxis therapy, low-dose aspirin therapy, and antibiotics therapy. Readers can find information about the key trends and developments in the market and market attractiveness analysis based on therapy type.
Based on route of administration, the market is segmented into oral, parenteral, and vaginal. In this chapter, readers can find information about the key trends and developments, followed by the analysis of market attractiveness based on route of administration of preterm birth prevention and management.
Based on patient type, the market is segmented into prior spontaneous PTB, preeclampsia, short cervix, chronic hypertension, insulin-dependent, twins, antiphospholipid antibody syndrome, and others. In this chapter, readers can find information about the key trends and developments birth prevention and management market and market attractiveness analysis based on patient type of preterm birth prevention and management.
This chapter provides details about the preterm birth prevention and management market on the basis of distribution channel, and has been classified into hospital pharmacies, retail pharmacies, drug stores, and mail order pharmacies. In this chapter, readers can understand the market attractiveness analysis based on distribution channel.
This chapter explains how the market will grow across various geographic regions, such as North America, Latin America, Europe, East Asia, South Asia, Oceania, and the Middle East & Africa (MEA).
This chapter includes a detailed analysis of the growth of the North America, along with a country-wise assessment that includes the U.S. and Canada.
Readers can find detailed information about several factors such as the pricing analysis, which are impacting growth of the Latin America market. This chapter also includes the growth prospects of the market in the leading Latin America countries such as Brazil, Mexico, and the Rest of Latin America.
Important growth prospects of the market based on its end users in several countries such as Germany, the UK, France, Spain, Italy, Russia, and the Rest of Europe, are included in this chapter.
India, Indonesia, Thailand, and Malaysia are among the leading countries in the South Asia region, which are the prime subjects of assessment to obtain the growth prospects of the South Asia preterm birth prevention and management market in this chapter. Readers can find detailed information about the growth parameters of the South Asia market during the period 2019-2029.
This chapter highlights the growth of the market in East Asia by focusing on China, Japan, and South Korea. This section also helps readers understand the key factors that are responsible for the growth of the market in East Asia.
In this chapter, Australia and New Zealand are among the leading countries in the Oceania region, which are the prime subjects of assessment to obtain the growth prospects of the Oceania market.
This chapter provides information about how the market will grow in the major countries in the MEA region such as GCC Countries, South Africa, Turkey, and the rest of MEA, during the forecast period.
This chapter provides information about how the market in emerging countries will grow during the forecast period.
In this chapter, readers can find detailed information about the tier analysis and market concentration of the key players in the preterm birth prevention and management market, along with their market presence analysis by region and product portfolio.
In this chapter, readers can find a comprehensive list of all the leading stakeholders in the market, along with detailed information about each company, which includes the company overview, revenue shares, strategic overview, and recent company developments. Some of the market players featured in the report are AMAG Pharmaceuticals, Ferring Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Allergan, Inc., AbbVie Inc., Aurobindo Pharma Limited, Bayer AG, Mylan N.V., Pfizer Inc., Merck & Co., Inc, Bausch Health Companies Inc., Novartis International AG, Sanofi S.A., and others.
This chapter includes a list of acronyms and assumptions that provide a base to the information and statistics included in this market report.
This chapter helps readers understand the research methodology followed to obtain the various conclusions as well as important qualitative and quantitative information about the preterm birth prevention and management market.
How the research was conducted?
- C - Level Executives
- Marketing Directors
- Sales Heads
- Portfolio Managers
- Purchasing Managers
- Medical Officers
- Device Development Heads
- Strategy Advisors
- R&D Managers
- Product Manufacturers
- Component Suppliers / OEMs
- Purchasing Departments
- Physicians / Nursing Managers
- Industry Experts
- Current Market Dynamics and Challenges
- Market Characteristics
- Market Performance and Growth Quadrants
- Competition Structure and Market Structure
- Strategic Growth Initiatives
- Product Adoption, utilization rate, substitutes
- Regulatory Landscape
- Products in Pipeline and Clinical Development
- Near-term and Long-term Market Growth Prospects
- Market Segment Splits and Authenticity
- Opinions on Market Projections and Validity of Assumptions
- Industry Magazines
- Organisation for Economic Co-operation and Development
- Emergency Care Research Institute
- Global Clinical Research Organizations
- Research organisations
- Company Press Releases
- Annual Reports and Investor Presentations
- Peer-reviewed Journals
- Government Websites and Publications
- Trade Websites
- Clinical Trial Registries
- Country-specific Regulatory Authorities
- World Bank, WHO,
Primary Interview Splits